Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Rheumatoid Arthritis | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD-refractory RA patients, therapies that are more effective in reducing the signs and symptoms of RA and that can sustain efficacy over time are needed. Novel agents able to demonstrate strong efficacy in these attributes will have substantial influence on physicians’ prescribing decisions for RA. We provide quantitative insight into U.S. and European rheumatologists’ perceptions of key treatment drivers and goals and the current level of unmet need in this indication. We analyze the commercial opportunities in the treatment of RA and discuss how emerging therapies can capitalize on these opportunities. Additionally, using an adaptive choice-based conjoint analysis, we offer an assessment of trade-offs, across clinical attributes and price, that can impact physicians’ prescribing likelihood and preference share of select target product profiles.

Questions Answered:

  • What are the treatment drivers and goals for RA?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for RA?
  • What are the prevailing areas of unmet need and opportunity in RA?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new RA drug?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in December 2016.

Key companies: AbbVie, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Incyte, Janssen, Pfizer, Roche

Key drugs: Humira, Remicade, Rituxan/MabThera, Orencia, Actemra/RoActemra, Xeljanz, baricitinib

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
north_east
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
north_east
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east